drugset / Trial / NCT05944185
Phase I/II Study of αPD1-MSLN-CAR T Cells in MSLN-positive Advanced Solid Tumors
Phase 1/2
Unknown
42 enrolled
Shanghai Cell Therapy Group Co.,Ltd
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · collab
NaSingle-groupOpen-labelTreatment
Summary
An open, multicenter, phase I/II study to evaluate the safety, tolerability, and effectiveness of αPD1-MSLN-CAR T cells in patients With MSLN-positive advanced solid tumors
Timeline
- Start
- 2023-09
- Primary completion
- 2024-09
- Completion
- 2025-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | αPD1-MSLN-CAR T cells | Cell therapy | — | — |